Prosecution Insights
Last updated: April 19, 2026
Application No. 18/384,195

Gummy Configuration

Non-Final OA §102§DP
Filed
Oct 26, 2023
Examiner
PALENIK, JEFFREY T
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Elevated Tech LLC
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
3y 5m
To Grant
81%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
466 granted / 867 resolved
-6.3% vs TC avg
Strong +27% interview lift
Without
With
+26.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
48 currently pending
Career history
915
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
46.2%
+6.2% vs TC avg
§102
20.8%
-19.2% vs TC avg
§112
18.5%
-21.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 867 resolved cases

Office Action

§102 §DP
DETAILED ACTION Status of the Application Receipt is acknowledged of Applicant’s claimed invention, filed 26 October 2023, in the matter of Application N° 18/384,195. Said documents have been entered on the record. The Examiner further acknowledges the following: The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . No additions, amendments, or cancellations have been made to the originally-filed claims. No new matter has been added. Thus, claims 1-14 represent all claims currently under consideration. Information Disclosure Statement No Information Disclosure Statements (IDS) have been filed for consideration. Claim Rejections - 35 USC §102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by THC & CBD Gummy Molds | Custom Silicone Molds; sold by www.vectormolds.com (herein referred to as “Vector”; image first appeared online on or before 7 December 2018). Vector discloses and depicts that the following THC/CBD gummies are able to be prepared from its molds: PNG media_image1.png 194 212 media_image1.png Greyscale PNG media_image2.png 197 206 media_image2.png Greyscale PNG media_image3.png 310 428 media_image3.png Greyscale The foregoing gummies are taught as THC/CBD gummies, thereby meeting the compositional limitations of claim 2. Regarding the recited shape, claim 1 is expressly met. The above gummies are individual bodies having a top surface and opposite bottom surface. The top and bottom surfaces are connected via a side wall that is in communication with both surfaces (appears as a channel that orbits the equator of the torus). The gummies are donut (torus) shaped and have a central opening. Around and formed into the top surface of the gummies are a plurality of recesses, each of which communicate across the top surface of the gummy, from the central opening (first end) to the outer, sidewall end (second end). Each of the recesses clearly extends into the top surface and defines a plurality of body sections, thereby allowing the gummy to be separable into substantially equal sections of the edible gummy material. The Examiner acknowledges the recitation of the claimed composition being separable by tearing. However, the Examiner respectfully submits that the manner in which the recited composition is separated is not at issue; only the compositional and structural elements of the claimed invention. The limitations of claims 3 and 4 recite that the recesses will have a lower surface defining a bottom thereof (i.e., bottom of the recess) and that said lower surface will be “U-shaped”. The Examiner submits that the practiced gummies meet this structural limitation. PNG media_image4.png 168 178 media_image4.png Greyscale The limitations of each of claims 5-8 recite that the second (outer) end of each recess extends between the top surface and bottom surface. The following closeup of the practiced gummy depicts this structural limitation: PNG media_image5.png 178 244 media_image5.png Greyscale Each of the limitations of claims 9-12 are also depicted in the above close-up. Therein, the lower surface of each recess (i.e., the floor of each recess) is shown as sloping down towards the outside of the gummy. The sloping starts higher on the first end (starting from the central hole end) and slopes downward and away toward the second (outer) end of the gummy. Lastly, the limitations of claims 13 and 14 are expressly disclosed by each of the pictures above. Each shows the plurality of recesses extending radially from the central opening of the gummy to the sidewall on the outer perimeter of the gummy. That is, all recesses would originate from a central point in the middle of the opening. Thus, the Vector reference is considered to meet each of the instantly claimed limitations. Nonstatutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-14 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of Zusman U.S. Design Patent No. D1,038,574 S (reference patent), in view of THC & CBD Gummy Molds | Custom Silicone Molds; sold by www.vectormolds.com (herein referred to as “Vector”; image first appeared online on or before 7 December 2018). Although the claims at issue are not identical, they are not patentably distinct from each other. At the outset, the Examiner directs Applicants to MPEP §804(II)(B)(7) regarding the rare instances when double patenting maybe at issue between an issued design patent and a pending utility patent. The limitations of instant claims 1-14 are discussed above. Reference claim 1 discloses: the ornamental design for a gummy, as shown and described. Figures 1-7 provide added structural design description to the claimed gummy. Reference Figure 1: Instant Figure 2: PNG media_image6.png 288 394 media_image6.png Greyscale PNG media_image7.png 440 584 media_image7.png Greyscale The disclosure in the reference patent is considered to read on each of the structural limitations recited by instant claims 1 and 3-14. The compositional limitation recited by claims 1-14 of a “gummy” is considered to teach the instantly recited “edible material” and “gummy composite material” limitations. Where Zusman is deficient is with respect to the pharmaceutical/nutritional supplement component recited by claim 2. Despite this deficiency, the Examiner submits that the disclosure would raise to the level of an obvious variant of the instantly claimed composition, particularly in view of the teachings provided by Vector, discussed above. Thus, were the published ‘574 patent available as prior art, the Examiner respectfully submits that it would minimally raise a clear showing of prima facie obviousness over the instant claimed edible gummy composition. Claims 1-14 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of Zusman U.S. Design Patent No. D1,038,576 S (reference patent), in view of THC & CBD Gummy Molds | Custom Silicone Molds; sold by www.vectormolds.com (herein referred to as “Vector”; image first appeared online on or before 7 December 2018). Although the claims at issue are not identical, they are not patentably distinct from each other. At the outset, the Examiner directs Applicants to MPEP §804(II)(B)(7) regarding the rare instances when double patenting maybe at issue between an issued design patent and a pending utility patent. The limitations of instant claims 1-14 are discussed above. Reference claim 1 discloses: the ornamental design for a gummy, as shown and described. Figures 1-7 provide added structural design description to the claimed gummy. Reference Figure 1: Instant Figure 2: PNG media_image8.png 326 368 media_image8.png Greyscale PNG media_image7.png 440 584 media_image7.png Greyscale The disclosure in the reference patent is considered to read on each of the structural limitations recited by instant claims 1 and 3-14. The compositional limitation recited by claims 1-14 of a “gummy” is considered to teach the instantly recited “edible material” and “gummy composite material” limitations. Where Zusman is deficient is with respect to the pharmaceutical/nutritional supplement component recited by claim 2. Despite this deficiency, the Examiner submits that the disclosure would raise to the level of an obvious variant of the instantly claimed composition, particularly in view of the teachings provided by Vector, discussed above. Thus, were the published ‘576 patent available as prior art, the Examiner respectfully submits that it would minimally raise a clear showing of prima facie obviousness over the instant claimed edible gummy composition. All claims have been rejected; no claims are allowed. Correspondence Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Jeffrey T. Palenik whose telephone number is (571) 270-1966. The Examiner can normally be reached on 9:30 am - 7:00 pm; M-F (EST). If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Jeffrey T. Palenik/ Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Oct 26, 2023
Application Filed
Feb 03, 2026
Non-Final Rejection — §102, §DP
Mar 19, 2026
Interview Requested
Mar 26, 2026
Examiner Interview Summary
Mar 26, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599701
DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12594359
Antimicrobial bone cement
2y 5m to grant Granted Apr 07, 2026
Patent 12589069
OPHTHALMIC SUSPENSION COMPOSITION
2y 5m to grant Granted Mar 31, 2026
Patent 12577400
Novel Topical Skin Closure Compositions and Systems
2y 5m to grant Granted Mar 17, 2026
Patent 12576071
PHARMACEUTICAL COMPOSITIONS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
81%
With Interview (+26.9%)
3y 5m
Median Time to Grant
Low
PTA Risk
Based on 867 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month